In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex

Clin Microbiol Infect. 2014 Dec;20(12):O1124-7. doi: 10.1111/1469-0691.12780. Epub 2014 Oct 3.

Abstract

The in vitro susceptibility profile to amikacin, linezolid, clarithromycin, imipenem, cefoxitin, clofazimine and tigecycline was established for 67 strains belonging to the Mycobacterium abscessus complex. Clofazimine and tigecycline were among the most effective drugs, prompting us to assess the effect of a clofazimine and tigecycline combination. Synergistic activity was found in 42% of the 19 isolates tested. The clinical impact of this new drug combination against the M. abscessus complex, as an alternative or sequential medication for the treatment of drug-resistant strains, remains to be addressed.

Keywords: Clofazimine; Mycobacterium abscessus; cystic fibrosis; drug susceptibility; tigecycline.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Drug Combinations
  • Drug Synergism
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium Infections, Nontuberculous / microbiology*
  • Nontuberculous Mycobacteria / drug effects*
  • Nontuberculous Mycobacteria / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Drug Combinations